Suliqua®, a fixed-ratio combination of basal insulin glargine and lixisenatide: role in the management of type 2 diabetes

Martin Buysschaert, Vanessa Preumont (1) Published in the journal : January 2019 Category : Diabétologie

Summary :

Suliqua® is a new fixed-ratio combination product of the basal insulin glargine 100U/mL and the GLP-1 receptor agonist lixisenatide. This article sought to analyze the recent literature to better identify the product’s potential advantages in general and more particularly, in comparison to basal insulin, and to clarify its precise place in the treatment algorithm for Type 2 diabetes in Belgium.

Key Words

Suliqua®, glargine, lixisenatide, HbA1c, weight, type 2 diabetes, indications

What does this article bring up for us?

Suliqua® is a new antihyperglycemic medication combining two antihyperglycemic agents with complementary actions. In Belgium, Suliqua® thus proves to be an interesting management option after failure of the association of oral therapies and basal insulin.